

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for prevention or treatment of arteriosclerosis or diseases derived from arteriosclerosis comprising an ADP receptor antagonist and an ACAT inhibitor.
2. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is selected from the group consisting of 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with dichloromethylenebisphosphonic acid, 2-(propylthio)-5'-adenylic acid, monoanhydride with dichloromethylene bis(phosphonic acid), methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate, 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, and pharmaceutically acceptable salts thereof.
3. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is N-[2-methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with dichloromethylene bisphosphonic acid or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate or a pharmaceutically acceptable salt thereof.

5

6. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate·sulfate.

10

7. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof.

15

8. The pharmaceutical composition according to claim 1, wherein the ADP receptor antagonist is 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine·hydrochloride.

20

9. The pharmaceutical composition according to any one of claims 1 or 2, wherein the ACAT inhibitor is selected from the group consisting of 2,6-bis(1-methylethyl)phenyl N-[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate, (S)-2',3',5'-trimethyl-4'-hydroxy- α -dodecylthio- α -phenylacetanilide, (-)-4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-dimethyl-1,3-dioxolan-2-yl}phenylphosphate, N-(2,6-diisopropylphenyl)-2-tetradecylthioacetamide, trans-1,4-bis[[1-cyclohexyl-3-(4-

25

30

dimethylaminophenyl)ureido)methyl]cyclohexane, 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridine-3-yl]urea, N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and
5 pharmaceutically acceptable salts thereof.

10. The pharmaceutical composition according to any one of claims 1 or 2, wherein the ACAT inhibitor is selected
10 from the group consisting of (±)-N-(1,2-diphenylethyl)-2-(2-octyloxyphenyl)acetamide, 2,6-bis(1-methylethyl)phenyl N-[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate, (1S,2S)-2-[N-(2,2-dimethylpropyl)-N-nonylcarbamoyl]aminocyclohexan-1-yl 3-[N-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate, (S)-
15 2',3',5'-trimethyl-4'-hydroxy-α-dodecylthio-α-phenylacetanilide, 2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol·hydrochloride, (-)-4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-dimethyl-1,3-dioxolan-2-yl}phenylphosphate monosodium salt, N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]-2-[4-[2-(oxazolo[4,5-b]pyridin-2-ylthio)ethyl]piperazin-1-yl]acetamide, N-(2,6-diisopropylphenyl)-2-tetradecylthioacetamide, trans-1,4-
25 bis[[1-cyclohexyl-3-(4-dimethylaminophenyl)ureido)methyl]cyclohexane, 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridine-3-yl]urea, N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide and a sulfate of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
30

11. The pharmaceutical composition according to any one of claims 1 or 2, wherein the ACAT inhibitor is selected from the group consisting of (S)-2',3',5'-trimethyl-4'-hydroxy- α -dodecylthio- α -phenylacetanilide, (-)-4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-dimethyl-1,3-dioxolan-2-yl}phenylphosphate, trans-1,4-bis[[1-cyclohexyl-3-(4-dimethylaminophenyl)ureido]methyl]cyclohexane, 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridin-3-yl]urea, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and
10 pharmaceutically acceptable salts thereof.

12. The pharmaceutical composition according to any one of claims 1 to 8, wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition according to any one of claims 1 to 8, wherein the ACAT inhibitor is a sulfate of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

14. A method for preventing or treating arteriosclerosis or a disease derived from arteriosclerosis by administering an effective amount of an ADP receptor antagonist and an ACAT inhibitor to a warm-blooded animal.

15. The method according to claim 14, wherein the ADP receptor antagonist is selected from the group consisting of 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with

dichloromethylenebisphosphonic acid, 2-(propylthio)-5'-adenylic acid, monoanhydride with dichloromethylene bis(phosphonic acid), methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate, 2-acetoxy-
5 5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, and pharmaceutically acceptable salts thereof.

16. The method according to claim 14, wherein the ADP
10 receptor antagonist is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof.

17. The method according to claim 14, wherein the ADP
15 receptor antagonist is N-[2-methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with dichloromethylene bisphosphonic acid or a pharmaceutically acceptable salt thereof.

20 18. The method according to claim 14, wherein the ADP receptor antagonist is methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate or a pharmaceutically acceptable salt thereof.

25 19. The method according to claim 14, wherein the ADP receptor antagonist is methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate.

20. The method according to claim 14, wherein the ADP
30 receptor antagonist is 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof.

21. The method according to claim 14, wherein the ADP
receptor antagonist is 2-acetoxy-5-(α -cyclopropylcarbonyl-
2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or
5 2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-
4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride.

22. The method according to any one of claims 14 or 15,
wherein the ACAT inhibitor is selected from the group
10 consisting of 2,6-bis(1-methylethyl)phenyl N-[[2,4,6-
tris(1-methylethyl)phenyl]acetyl]sulfamate, (S)-2',3',5'-
trimethyl-4'-hydroxy- α -dodecylthio- α -phenylacetanilide, (-
) -4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-
dimethyl-1,3-dioxolan-2-yl}phenylphosphate, N-(2,6-
15 diisopropylphenyl)-2-tetradecylthioacetamide, trans-1,4-
bis[[1-cyclohexyl-3-(4-
dimethylaminophenyl)ureido]methyl]cyclohexane, 1-benzyl-1-
[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-
methylpyridine-3-yl]urea, N-(4,6-dimethyl-1-pentylindolin-
20 7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-carboxymethyl-
4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and
pharmaceutically acceptable salts thereof.

23. The method according to any one of claims 14 or 15,
25 wherein the ACAT inhibitor is selected from the group
consisting of (\pm)-N-(1,2-diphenylethyl)-2-(2-
octyloxyphenyl)acetamide, 2,6-bis(1-methylethyl)phenyl N-
[[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate,
(1S,2S)-2-[N-(2,2-dimethylpropyl)-N-
30 nonylcarbamoyl]aminocyclohexan-1-yl 3-[N-(2,2,5,5-
tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate, (S)-
2',3',5'-trimethyl-4'-hydroxy- α -dodecylthio- α -

phenylacetanilide, 2-[3-(2-cyclohexylethyl)-3-(4-dimethylaminophenyl)ureido]-4-methoxy-6-tert-butylphenol·hydrochloride, (-)-4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-dimethyl-1,3-dioxolan-2-yl}phenylphosphate·monosodium salt, N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]-2-[4-[2-(oxazolo[4,5-b]pyridin-2-ylthio)ethyl]piperazin-1-yl]acetamide, N-(2,6-diisopropylphenyl)-2-tetradecylthioacetamide, trans-1,4-bis[[1-cyclohexyl-3-(4-dimethylaminophenyl)ureido]methyl]cyclohexane, 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridine-3-yl]urea, N-(4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide and a sulfate of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

24. The method according to any one of claims 14 or 15, wherein the ACAT inhibitor is selected from the group consisting of (S)-2',3',5'-trimethyl-4'-hydroxy- α -dodecylthio- α -phenylacetanilide, (-)-4-{(4R,5R)-2-[3-(2,6-diisopropylphenyl)ureidomethyl]-4,5-dimethyl-1,3-dioxolan-2-yl}phenylphosphate, trans-1,4-bis[[1-cyclohexyl-3-(4-dimethylaminophenyl)ureido]methyl]cyclohexane, 1-benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridin-3-yl]urea, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and pharmaceutically acceptable salts thereof.

25. The method according to any one of claims 14 to 21, wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmaceutically acceptable salt thereof.

26. The method according to any one of claims 14 to 21, wherein the ACAT inhibitor is a sulfate of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

5

27. The method according to claim 14, wherein the warm-blooded animal is human and total dosage amount per day of ADP receptor antagonist and ACAT inhibitor for oral administration is 0.1 to 1000 mg and for parenteral

10

administration is 0.01 to 100 mg.